Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIBET: Trifluridine/Tipiracil in ER-positive, HER2-negative Advanced Breast Cancer
NCT04489173Phase 2Completed
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in breast cancer, sponsored by Borstkanker Onderzoek Groep. Started Sep 2020; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04489173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489173.